The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening

British Journal of Cancer

Volumn 100, Issue 8, 2009, Pages 1240-1244

  De Kok, I M C M ^a   Polder, J J ^b   Habbema, J D F ^a   Berkers, L M ^a   Meerding, W J ^a   Rebolj, M ^a   Van Ballegooijen, M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Cost effectiveness; Economic evaluation; Screening

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CALCULATION; CANCER SCREENING; CAUSE OF DEATH; CHILD; COLON CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DYING; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH PROGRAM; HOME CARE; HUMAN; LIFE; LUNG CANCER; MALE; MORTALITY; NETHERLANDS; NURSING HOME; PRIORITY JOURNAL; PROSTATE CANCER; UTERINE CERVIX CANCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; CHILD; CONFIDENCE INTERVALS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, ECONOMIC; NEOPLASMS; NETHERLANDS;

EID: 64949094136     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605018     Document Type: Article

References (25)

1. Bonneux L, Barendregt JJ, Nusselder WJ, der Maas PJ (1998) Preventing fatal diseases increases healthcare costs: cause elimination life table approach. BMJ 316: 26-29
2. Eakin EG, Youlden DR, Baade PD, Lawler SP, Reeves MM, Heyworth JS, Fritschi L (2007) Health behaviors of cancer survivors: data from an Australian population-based survey. Cancer Causes Control 18: 881-894
3. Gandjour A, Lauterbach KW (2005) Does prevention save costs? Considering deferral of the expensive last year of life. J Health Econ 24: 715-724
4. Garber AM, Phelps CE (1997) Economic foundations of cost-effectiveness analysis. J Health Econ 16: 1-31
5. Garber AM, Weinstein MC, Torrance GW, Kamlet MS (1996) Theoretical foundations of cost-effectiveness analysis. In Cost-Effectiveness in Health and Medicine, Gold MR, Russel L, Weinstein M (eds) pp 45-47. University Press: Oxford
6. Groenewoud JH, Pijnappel RM, van den Akker-Van Marle ME, Birnie E, Buijs-van der Woude T, Mali WP, de Koning HJ, Buskens E (2004) Cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open-breast biopsy. Br J Cancer 90: 383-392
7. Kardamanidis K, Lim K, Da Cunha C, Taylor LK, Jorm LR (2007) Hospital costs of older people in New South Wales in the last year of life. Med J Aust 187: 383-386
8. Koroukian SM, Beaird H, Madigan E, Diaz M (2006) End-of-life expenditures by Ohio Medicaid beneficiaries dying of cancer. Health Care Financ Rev 28: 65-80
9. Liljas B, Karlsson GS, Stalhammar NO (2008) On future non-medical costs in economic evaluations. Health Econ 17: 579-591
10. Meltzer D (1997) Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16: 33-64
11. Netherlands Cancer Registry (NCR) (2005) Breast cancer mortality by age. www.ikcnet.nl
12. Nyman JA (2004) Should the consumption of survivors be included as a cost in cost-utility analysis? Health Econ 13: 417-427
13. Pignone M, Saha S, Hoerger T, Mandelblatt J (2002) Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 137: 96-104
14. Polder JJ, Barendregt JJ, van Oers H (2006) Health care costs in the last year of life-the Dutch experience. Soc Sci Med 63: 1720-1731
15. Riley G, Lubitz J, Prihoda R, Rabey E (1987) The use and costs of Medicare services by cause of death. Inquiry 24: 233-244
16. Riley GF, Lubitz JD (1989) Longitudinal patterns of Medicare use by cause of death. Health Care Financ Rev 11: 1-12
17. Russell LB, Siegel JE, Daniels N, Gold MR, Luce BR, Mandelblatt JS (1996) Cost-effectiveness analysis as a guide to resource allocation in health: roles and limitations. In Cost-effectiveness in Health and Medicine, Gold MR, Russel L, Weinstein M (eds) pp 3-5. University Press: Oxford
18. Soerjomataram I (2007) Multiple primary cancers in patients with breast and skin cancer. In Department of Public Health. Erasmus University: Rotterdam
19. Statistics Netherlands (2007) Overlevingskansen; leeftijd, geslacht, 1996-2000: Voorburg. http://statline.cbs.nl/StatWeb/publication/?DM=SLNL&PA= 37450&D1=3&D2=a&D3=a&D4=27&HDR=T,G1&STB=G2,G3&VW=T. Internet accessed 19 March 2009
20. Statistics Netherlands (2008) Onverzekerden tegen ziektekosten; 1995-2005: Voorburg/Heerlen. http://statline.cbs.nl/StatWeb/publication/?DM= SLNL&PA=7407&D1=1-6,9&D2=(1-11)-l&VW=T. Internet accessed 19 March 2009
21. Stone PW, Teutsch S, Chapman RH, Bell C, Goldie SJ, Neumann PJ (2000) Cost-utility analyses of clinical preventive services: published ratios, 1976-1997. Am J Prev Med 19: 15-23
22. van Baal PH, Feenstra TL, Hoogenveen RT, de Wit GA, Brouwer WB (2007) Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a 'perfect' cost-utility ratio. Health Econ 16: 421-433
23. van Ballegooijen M, Rebolj M, Essink-Bot ML, Meerding WJ, Berkers LM, Habbema JDF (2006) De effecten en kosten van het bevolkingsonderzoek naar baarmoederhalskanker in Nederland na de herstructurering. Erasmus MC, afdeling Maatschappelijke Gezondheidszorg: Rotterdam
24. Wong A, de Bruin A, van Hilten O, Kommer GJ, Polder JJ (2006) Groot-en kleingebruikers van ziekenhuiszorg. In Gezondheid en zorg in cijfers 2006 van Hilten O, Mares AMHM (eds). Centraal Bureau voor de Statistiek (Statistics Netherlands): Voorburg
25. World Health Organisation (WHO) (16/02/2009). Per capita total expenditure on health in the Netherlands (PPP int. $), by period. http://www.who.int/whosis/